A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers

[1]  Ramazan Erdem,et al.  Preparation and Characterization of Polyethylene Glycol Functional Hydroxyapatite/Polycaprolactone Electrospun Biomembranes for Bone Tissue Engineering Applications , 2021, Fibers and Polymers.

[2]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[3]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[4]  K. Selting,et al.  Physical Properties of Nanoparticles That Result in Improved Cancer Targeting , 2020, Journal of oncology.

[5]  R. García-Valls,et al.  Encapsulation for Cancer Therapy , 2020, Molecules.

[6]  R. Pasricha,et al.  pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics , 2020, Communications Biology.

[7]  Qiang Wang,et al.  pH-responsive nanoparticles based on optimized synthetic amphiphilic poly(β-amino esters) for doxorubicin delivery , 2020 .

[8]  H. Aldawsari,et al.  Rapid Microwave-Assisted Cisplatin-Loaded Solid Lipid Nanoparticles: Synthesis, Characterization and Anticancer Study , 2020, Nanomaterials.

[9]  P. Mura.  Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: a review. , 2020, International journal of pharmaceutics.

[10]  Yuxin Yin,et al.  Erythrocyte-mimicking paclitaxel nanoparticles for improving biodistributions of hydrophobic drugs to enhance antitumor efficacy , 2020, Drug delivery.

[11]  Ruixue Cui,et al.  Synergism of cisplatin-oleanolic acid co-loaded hybrid nanoparticles on gastric carcinoma cells for enhanced apoptosis and reversed multidrug resistance , 2020, Drug delivery.

[12]  A. Akbarzadeh,et al.  Preparation and characterization of novel anti-inflammatory biological agents based on piroxicam-loaded poly-ε-caprolactone nano-particles for sustained NSAID delivery , 2020, Drug delivery.

[13]  Yen-Hsiang Chang,et al.  Encapsulation of gadolinium ferrite nanoparticle in generation 4.5 poly(amidoamine) dendrimer for cancer theranostics applications using low frequency alternating magnetic field. , 2019, Colloids and surfaces. B, Biointerfaces.

[14]  M. Vossoughi,et al.  Doxorubicin/Cisplatin-Loaded Superparamagnetic Nanoparticles As A Stimuli-Responsive Co-Delivery System For Chemo-Photothermal Therapy , 2019, International journal of nanomedicine.

[15]  Yuanyuan Liu,et al.  pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer , 2019, Journal of Nanobiotechnology.

[16]  H. Akça,et al.  NF-κB-Induced Upregulation of miR-548as-3p Increases Invasion of NSCLC by Targeting PTEN. , 2019, Anti-cancer agents in medicinal chemistry.

[17]  Marjan Ghorbani,et al.  A novel smart PEGylated gelatin nanoparticle for co-delivery of doxorubicin and betanin: A strategy for enhancing the therapeutic efficacy of chemotherapy. , 2019, Materials science & engineering. C, Materials for biological applications.

[18]  Jing Liu,et al.  Photothermally controlled drug release system with high dose loading for synergistic chemo-photothermal therapy of multidrug resistance cancer. , 2019, Colloids and surfaces. B, Biointerfaces.

[19]  Shuyun Yang,et al.  Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial‐mesenchymal transition and modulating SIRT1/β‐catenin signaling pathway in breast cancer , 2019, Cancer medicine.

[20]  Jiang Liu,et al.  FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[21]  Y. Choi,et al.  Correction to: Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics , 2018, Journal of Pharmaceutical Investigation.

[22]  T. Tourville,et al.  Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. , 2018, American journal of physiology. Cell physiology.

[23]  S. Linn,et al.  Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). , 2018, European journal of cancer.

[24]  B. Denard,et al.  CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy , 2018, BMC Cancer.

[25]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[26]  Y. Choi,et al.  Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics , 2017, Journal of Pharmaceutical Investigation.

[27]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[28]  H. Akça,et al.  Pl3K/Akt/NF-κB Signalling Pathway on NSCLC Invasion. , 2016 .

[29]  N. Samadi,et al.  Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells , 2016, Molecular Biology Reports.

[30]  Jian Huang,et al.  NF-κB Expression and Outcomes in Solid Tumors , 2015, Medicine.

[31]  F. Hu,et al.  Knockdown of the inflammatory factor pentraxin-3 suppresses growth and invasion of lung adenocarcinoma through the AKT and NF-kappa B pathways. , 2014, Journal of biological regulators and homeostatic agents.

[32]  M. Aslan,et al.  Neutral sphingomyelinase inhibition decreases ER stress-mediated apoptosis and inducible nitric oxide synthase in retinal pigment epithelial cells. , 2013, Free radical biology & medicine.

[33]  T. Ozben,et al.  N‐acetyl‐L‐cysteine inhibits bleomycin induced apoptosis in malignant testicular germ cell tumors , 2013, Journal of cellular biochemistry.

[34]  Arun Sharma,et al.  Nanocarriers for Diagnosis and Targeting of Breast Cancer , 2013, BioMed research international.

[35]  E. Gavilan,et al.  GSK-3β signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition , 2013, Cell Death and Disease.

[36]  Jennifer L. Thompson.  Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma , 2013, The Annals of pharmacotherapy.

[37]  P. L. McCormack,et al.  Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. , 2012, Drugs.

[38]  Raj Kumar,et al.  Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. , 2012, Cancer letters.

[39]  Nicholas A Peppas,et al.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. , 2012, Nano today.

[40]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Zhuogang Liu,et al.  The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. , 2012, Die Pharmazie.

[42]  Jan E Schnitzer,et al.  Overcoming in vivo barriers to targeted nanodelivery. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[43]  Po-Len Liu,et al.  High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. , 2010, American journal of respiratory cell and molecular biology.

[44]  Jun Yu,et al.  Proteasome inhibition: a new therapeutic strategy to cancer treatment. , 2010, Cancer letters.

[45]  V. Seifert,et al.  Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL‐induced apoptosis , 2008, The FEBS journal.

[46]  Xiaohua Li,et al.  Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp , 2008, Cancer biology & therapy.

[47]  A. P. Padilla,et al.  Intrinsic viscosity of bovine serum albumin conformers. , 2008, International journal of biological macromolecules.

[48]  Zhaoming Ye,et al.  Caspase‐8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132 , 2007, Cell biology international.

[49]  A. Strasser,et al.  Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway , 2007, Oncogene.

[50]  S. Gibson,et al.  The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells , 2006, Apoptosis.

[51]  T. Fujita,et al.  Proteasome inhibitors can alter the signaling pathways and attenuate the P‐glycoprotein‐mediated multidrug resistance , 2005, International journal of cancer.

[52]  L. Pfeffer,et al.  Interferon Induces NF-κB-inducing Kinase/Tumor Necrosis Factor Receptor-associated Factor-dependent NF-κB Activation to Promote Cell Survival* , 2005, Journal of Biological Chemistry.

[53]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Orlowski,et al.  Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role , 2004, Molecular Pharmacology.

[55]  Chung-Soo Lee,et al.  Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents. , 2004, Biochemical pharmacology.

[56]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[57]  V. H. Lee,et al.  Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. , 2003, Molecular vision.

[58]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[59]  Wan-Wan Lin,et al.  Proteasome inhibitors stimulate activator protein‐1 pathway via reactive oxygen species production , 2002, FEBS letters.

[60]  A. Asai,et al.  Proteasome Inhibitors Induce Cytochrome c–Caspase-3-Like Protease-Mediated Apoptosis in Cultured Cortical Neurons , 2000, The Journal of Neuroscience.

[61]  K. Tanaka,et al.  Proteasomes: structure and biology. , 1998, Journal of biochemistry.

[62]  K. Anand,et al.  Synthetic, Natural Derived Lipid Nanoparticles and Polymeric Nanoparticles Drug Delivery Applications , 2020 .

[63]  B. Fischer.  Lessons Learned. , 2016, Schizophrenia bulletin.

[64]  P. de Souza,et al.  Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer. , 2015, Biomaterials science.

[65]  Yaqin Tu,et al.  The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. , 2012, International journal of clinical and experimental pathology.

[66]  A. Tsimokha,et al.  Role of proteasomes in cellular regulation. , 2008, International review of cell and molecular biology.

[67]  C. Brancolini.  Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated? , 2008, Current molecular pharmacology.

[68]  Jian Jian Li,et al.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. , 2006, Anticancer research.

[69]  L. Pfeffer,et al.  Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. , 2005, The Journal of biological chemistry.

[70]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[71]  J C Baker,et al.  Regulation of enzyme activity by glucagon: increased hormonal activity of iodinated glucagon. , 1975, Advances in enzyme regulation.

[72]  P. Calabresi,et al.  Chemotherapy of neoplastic diseases. , 1962, Annual review of medicine.

[73]  D. Karnofsky,et al.  Chemotherapy of neoplastic diseases. , 1950, The Medical clinics of North America.